Organization | Vac4All

Vac4All Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2011

NCT01341704

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

CEO, Vac4All | Vac4All

Active Ingredients

Drugs in Phase 2 Trials (5)

aluminum hydroxide (Gaviscon) (2 trials)

inactivated rabies vaccine (Imovax) (2 trials)

msp3-crm-vac4all (2 trials)

msp3-lsp/aloh (1 trial)

pfpebs (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Malaria (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 5